Chronic daily administration of oral etoposide in refractory lymphoma

Bender, 1978, Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin's lymphoma, Am J Hematol, 5, 203, 10.1002/ajh.2830050305 McElwain, 1984, Etoposide in combination for the treatment of Hodgkin's disease, 293 Fisher, 1983, Diffuse aggressive lymphoma: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy, Ann Intern Med, 98, 304, 10.7326/0003-4819-98-3-304 Cabanillas, 1987, Results of MIME salvage regimen for recurrent or refractory lymphoma, J Clin Oncol, 5, 407, 10.1200/JCO.1987.5.3.407 Spitzer, 1980, High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumours, Cancer, 45, 3075, 10.1002/1097-0142(19800615)45:12<3075::AID-CNCR2820451233>3.0.CO;2-8 Dombernowsky, 1973, Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia, Acta Path Microbiol Scand A, 81, 715 Slevin, 1989, A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer, J Clin Oncol, 7, 1333, 10.1200/JCO.1989.7.9.1333 Hainsworth, 1989, Chronic daily administration of oral etoposide—a phase I trial, J Clin Oncol, 7, 396, 10.1200/JCO.1989.7.3.396 Cecil, 1978, Evaluation of VP 16-213 in malignant lymphoma and melanoma, Cancer Treat Rep, 62, 801 1973, Epipodophyllotoxin VP 16-213 in treatment of acute leukaemias, haematosarcomas, and solid tumours, Br Med J, 3, 199, 10.1136/bmj.3.5873.199 Mathe, 1974, Two epipodophyllotoxin derivatives, VM26 and VP16-213, in the treatment of leukaemias, hematosarcomas, and lymphomas, Cancer, 34, 985, 10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO;2-U Nissen, 1972, Phase I clinical trial of a new antitumor agent, 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidine-β-D-glucopyranoside (NSC 141540); VP16-213, Cancer Chemother Rep, 56, 769 Kroner, 1982, Etoposide as single agent and in combination with cis-platinum for malignant lymphomas, Cancer Treat Rev, 9, 39, 10.1016/S0305-7372(82)80076-5 Schmoll, 1982, Review of etoposide single-agent activity, Cancer Treat Rev, 9, 21, 10.1016/S0305-7372(82)80074-1 Rowe, 1984, Identification of the breakage-reunion subunit of T4 DNA topoisomerase, J Biol Chem, 259, 9177, 10.1016/S0021-9258(17)47281-4 van Maanen, 1988, Mechanism of action of antitumor drug etoposide: a review, J Natl Cancer Inst, 80, 1526, 10.1093/jnci/80.19.1526 Cavalli, 1978, VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules, Cancer Treat Rep, 62, 473 Roed, 1987, The effect of the two epipodophyllotoxin derivatives etoposide (VP16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung, Cancer Chemother Pharmacol, 19, 16, 10.1007/BF00296248 Miller, 1989, Phase II study of daily oral VP-16 in refractory germ cell tumors, 8, 145 Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol (in press).